Effect of different retention times of wrist-ankle acupuncture(WAA) on pain in gastric cancer chemotherapy patients based on symptom clusters: a randomised controlled trial

注册号:

Registration number:

ITMCTR2200005930

最近更新日期:

Date of Last Refreshed on:

2022-04-28

注册时间:

Date of Registration:

2022-04-28

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于症状群的腕踝针对胃癌化疗患者疼痛干预效果与留针时间关系研究

Public title:

Effect of different retention times of wrist-ankle acupuncture(WAA) on pain in gastric cancer chemotherapy patients based on symptom clusters: a randomised controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于症状群的腕踝针对胃癌化疗患者疼痛干预效果与留针时间关系研究

Scientific title:

Effect of different retention times of wrist-ankle acupuncture(WAA) on pain in gastric cancer chemotherapy patients based on symptom clusters

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200059294 ; ChiMCTR2200005930

申请注册联系人:

杨丽萍

研究负责人:

杨丽萍

Applicant:

Yang Liping

Study leader:

Yang Liping

申请注册联系人电话:

Applicant telephone:

13701475107

研究负责人电话:

Study leader's telephone:

13701475107

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yanglp1987@126.com

研究负责人电子邮件:

Study leader's E-mail:

yanglp1987@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市秦淮区汉中路155号江苏省中医院护理部

研究负责人通讯地址:

江苏省南京市秦淮区汉中路155号江苏省中医院护理部

Applicant address:

Nursing Department, Jiangsu Hospital of Traditional Chinese Medicine, 155 Hanzhong Road, Qinhuai District, Nanjing city, Jiangsu Province

Study leader's address:

Nursing Department, Jiangsu Hospital of Traditional Chinese Medicine, 155 Hanzhong Road, Qinhuai District, Nanjing city, Jiangsu Provinc

申请注册联系人邮政编码:

Applicant postcode:

210000

研究负责人邮政编码:

Study leader's postcode:

210000

申请人所在单位:

江苏省中医院

Applicant's institution:

, Jiangsu Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省中医院

Primary sponsor:

Jiangsu Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

江苏省南京市秦淮区汉中路155号江苏省中医院护理部

Primary sponsor's address:

Nursing Department, Jiangsu Hospital of Traditional Chinese Medicine, 155 Hanzhong Road, Qinhuai District, Nanjing city, Jiangsu Provinc

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省中医院

具体地址:

江苏省南京市秦淮区汉中路155号

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Address:

155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province, China

经费或物资来源:

江苏省中医院医学发展医疗救助基金会

Source(s) of funding:

Medical Aid Foundation of Jiangsu Hospital of Traditional Chinese Medicine

研究疾病:

胃癌

研究疾病代码:

Target disease:

gastric cancer

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

I期临床试验

Phase I clinical trial

研究目的:

1)确定WAA联合镇痛药物治疗是否比单用镇痛药物对于胃癌化疗患者的镇痛效果好 2)确定WAA组的疼痛、疲乏、睡眠障碍症状群的严重程度、苦恼、生活困扰度是否比对照组改善更多 3)探讨何种留针时间的WAA对于胃癌化疗患者的疼痛、疲乏、睡眠障碍症状群管理更加高效 4)探讨WAA联合镇痛药物治疗胃癌化疗患者疼痛是否安全

Objectives of Study:

1.evaluate whether WAA combined with analgesic medication is more effective than analgesic medication alone for analgesia in gastric cancer patients undergoing chemotherapy. 2.determine whether the symptom clusters severity,distress and interference with daily life in the WAA group improved more than in the control group 3.analyze whether type of needle retention time WAA is more effective in the management of pain,fatigue,sleep disturbance symptom clusters in gastric cancer patients undergoing chemotherapy. 4.explore the safety of WAA combined with analgesics.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.病理学检查诊断为原发性胃癌并行化疗者; 2.年龄18-75周岁; 3.符合条件的患者报告了过去一周的疼痛、疲劳和睡眠障碍,三种症状中至少有两种的严重程度为>3(0-10数字分级标准[NRS])。 4.预计生存期大于3个月; 5.患者意识清晰,对自身症状有感知判断能力,且能合作评分; ⑥ 患者知情同意并愿意参加本研究。

Inclusion criteria

1.Patients who have a pathological diagnosis of primary gastric cancer and are undergoing chemotherapy. 2.patients ranging in age from 18 to 75 years. 3.Eligible individuals who have reported pain, fatigue, or sleep disturbance in the past week, with at least two of the three symptoms having a severity of >3. (0-10 NRS). 4.Expected survival time is longer than 3 months. 5.The patient is conscious, can perceive and appraise his or her symptoms, and cooperates in scoring. 6.patients submitted informed consent and agreed to participate in this investigation.

排除标准:

1.除药物止痛治疗之外,曾经或者正在使用止痛性放疗、硬膜外镇痛泵或者神经阻断治疗; 2.对口服镇痛药物过敏者; 3.既往有针灸晕针史患者; 4.皮肤敏感、破溃者; 5合并严重的心、脑、肝、肾等功能障碍、造血系统功能不全的患者; 6.患者在治疗期间进行其他中医外治法治疗

Exclusion criteria:

1.Patients who have had or are currently undergoing analgesic treatment, epidural analgesic pumps, or pharmaceutical analgesia such as nerve blocks. 2.Patients who are allergic to analgesics taken orally. 3.Acupuncture dizziness in the past. 4.Sensitive, cracked skin 5.Patients who have significant cardiac, cerebral, hepatic, or renal dysfunction as well as haematopoietic insufficiency. 6.Other TCM external therapies are being received during the treatment period.

研究实施时间:

Study execute time:

From 2022-05-24

To      2023-05-24

征募观察对象时间:

Recruiting time:

From 2022-05-24

To      2023-05-24

干预措施:

Interventions:

组别:

腕踝针组2

样本量:

33

Group:

WAA group2

Sample size:

干预措施:

三阶梯镇痛+腕踝针留针30min

干预措施代码:

Intervention:

Three steps of analgesia+WAA retained for 30min

Intervention code:

组别:

腕踝针组3

样本量:

33

Group:

WAA group3

Sample size:

干预措施:

三阶梯镇痛+腕踝针留针60min

干预措施代码:

Intervention:

Three steps of analgesia+WAA retained for 60min

Intervention code:

组别:

腕踝针组1

样本量:

33

Group:

WAA group1

Sample size:

干预措施:

三阶梯镇痛+腕踝针留针20min

干预措施代码:

Intervention:

Three steps of analgesia+WAA retained for 20min

Intervention code:

组别:

对照组

样本量:

33

Group:

Control group

Sample size:

干预措施:

三阶梯镇痛疗法

干预措施代码:

Intervention:

Three steps of analgesia

Intervention code:

样本总量 Total sample size : 132

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省中医院

单位级别:

三级甲等中医院

Institution/hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital of Traditional Chinese Medicine

测量指标:

Outcomes:

指标中文名:

胃癌患者生活质量

指标类型:

次要指标

Outcome:

Quality of life in patients with gastric cancer

Type:

Secondary indicator

测量时间点:

治疗前,首次治疗后1周

测量方法:

欧洲癌症研究和治疗组织生活问卷-胃癌

Measure time point of outcome:

Before treatment and 1 week after initial treatment

Measure method:

The EORTC QLQ-STO52

指标中文名:

安全性评估

指标类型:

副作用指标

Outcome:

Safety assessment

Type:

Adverse events

测量时间点:

治疗前,治疗后24h,48h,72h首次治疗后1周

测量方法:

观察记录单

Measure time point of outcome:

Before treatment, 24h,48h,72h after treatment 1 week after initial treatment,

Measure method:

Observation record sheet

指标中文名:

疼痛强度

指标类型:

主要指标

Outcome:

pain intensity

Type:

Primary indicator

测量时间点:

首次治疗后24h,48h,72h

测量方法:

数字分级标准(NRS)

Measure time point of outcome:

24 hours, 48 hours, and 72 hours after the first treatment

Measure method:

The Numerical Rating Scale (NRS)

指标中文名:

疼痛-疲乏-睡眠障碍症状群苦恼

指标类型:

主要指标

Outcome:

pain,fatigue sleep disturbance symptom cluster distress

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛-疲乏-睡眠障碍症状群严重程度、生活困扰度

指标类型:

主要指标

Outcome:

pain,fatigue sleep disturbance symptom cluster severity, interference with daily life

Type:

Primary indicator

测量时间点:

治疗前,首次治疗后1周

测量方法:

安德森症状评估量表

Measure time point of outcome:

Before treatment and 1 week after initial treatment

Measure method:

The MD Anderson Symptom Inventory (MDSAI)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

在招募前由不参与本研究的统计人员通过SPSS.26产生与样本编号相对应的随机序列号,随机分为4组

Randomization Procedure (please state who generates the random number sequence and by what method):

Before recruitment, statisticians not involved in this study generated random serial numbers corresponding to sample numbers through SPSS.26, and randomly divided into 4 groups

盲法:

干预者无法做到盲法,但是不允许向评估者透露提供任何有关分组和治疗程序的信息。数据统计分析者由不参与本试验招募、实施、数据收集的独立人员进行。

Blinding:

The intervenor could not be blinded, but was not allowed to disclose any information about grouping and treatment procedures to the evaluator. Data statistical analysis was conducted by independent personnel who were not involved in the recruitment, implementation and data collection of this study.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后可以给主要负责人发邮件索取原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the test is completed, you can email the main person in charge to request the original data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表,江苏省中医院电子病例系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF,Electronic case system of Jiangsu Hospital of Traditional Chinese Medicine

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above